Trump Issues Executive Order Intended to Lower Medicare Drug Costs

The White House issued an executive order in an attempt to lower Medicare drug costs. The order forces drug makers to use foreign drug pricing as a benchmark for how drugs are priced in the U.S.

Published August 5, 2020

Follow our Medicare Coronavirus News page for related information on coronavirus (COVID-19) and its impact on Medicare beneficiaries.

President Trump issued an executive order on July 24 intended to lower prescription drug prices for Medicare by linking drug costs to the prices paid for the same drug in other countries. The order also allows Medicare beneficiaries to purchase medication imported from Canada. 

Find a $0 premium Medicare Advantage plan today.

Speak with a licensed insurance agent

1-800-557-6059

The order that ties prescription drugs to international benchmarks, known as the “most-favored-nations rule,” will not go into effect until Aug. 24. Pharmaceutical companies have until then to come up with alternative measures for lowering the costs of their drugs. 

Health officials estimate the move can save Medicare $17 billion in the first five years. Medicare spent $335 billion on prescription drugs in 2018.

Further measures to lower insulin costs and reform drug reimbursement

There were additional action items included in Trump’s recent orders.

One measure involves stripping away legal protections for reimbursements that drug manufacturers make to middlemen and insurance plans that provide drug coverage through Medicare or Medicaid. 

Because these reimbursements are typically based on the price of the drug, drugmakers are incentivized to charge higher drug prices. Trump’s orders would implement a flat-fee reimbursement.

Another aspect of the executive orders requires health centers that use the federal drug discount program to pass on any resulting savings on insulin or insulin pens to patients.

Drugmakers and democrats push back on Trump’s orders

The executive order was not well received by everyone. Drugmakers and democrats had concerns about the effects the executive orders could have.

  • Medicare drug coverage premiums could rise as pharmaceutical companies attempt to recoup the loss of revenue due to reduced prices.

  • Drug manufacturers currently working on a COVID-19 vaccine may have to divert current efforts to develop a vaccine and effective treatments for the disease caused by the novel coronavirus.

Several top pharmaceutical companies requested a White House meeting concerning the issue. The meeting was scheduled for July 28 but was later cancelled after major drug lobbies refused to send representatives.

Learn more about Medicare news and how the 2020 election may affect beneficiaries.

Christian

About the author

Christian Worstell is a licensed insurance agent and a Senior Staff Writer for MedicareAdvantage.com. He is passionate about helping people navigate the complexities of Medicare and understand their coverage options.

His work has been featured in outlets such as Vox, MSN, and The Washington Post, and he is a frequent contributor to health care and finance blogs.

Christian is a graduate of Shippensburg University with a bachelor’s degree in journalism. He currently lives in Raleigh, NC.

Where you've seen coverage of Christian's research and reports:

MarketWatch logo

Yahoo Finance logo 

 

WebMD Logo

South Florida Sun Sentinel Logo

WRAL.com Logo

Deseret News Logo

Healthcare Finance Logo